Background <p>Mapping national drug terminologies to internationally recognized standards is essential for harmonising health data across regions and supporting secondary data use. In Austria, the national drug terminology lacks fine-granular mappings to RxNorm and RxNorm Extension (RxN/E), limiting its integration into the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). This study aims to semiautomatically map Austria’s national drug terminology to RxN/E, to enable improved interoperability and data standardisation for secondary use.</p> Methods <p>We implemented a semiautomated mapping approach using public supplementary data to bridge the gap between national drug concepts and RxN/E concepts. Probabilistic matching and hierarchical refinement techniques were applied to derive finer-grained and more meaningful mappings than previously available ingredient level mappings via the Anatomical Therapeutic Chemical (ATC) classification. We linked our mappings to other available European drug mappings for a validation of our results.</p> Results <p>Our process successfully mapped 18,390 (95.42%) of Austria’s 19,273 drug concepts to RxN/E, surpassing previous mappings that focused solely on ingredient-level relationships. Specifically, we mapped 73.65% of the concepts to more specific RxN/E targets, such as branded drug boxes and quantified clinical drugs. We identified multiple vocabulary inconsistencies, including duplications and erroneous relationships within RxN/E, which were documented for improvement. The results are disseminated as Usagi-formatted CSV files and HL7 FHIR ConceptMaps to encourage transparency, ease of use, and community-driven refinement.</p> Conclusions <p>The presented mapping approach highlights the feasibility and utility of leveraging publicly available supplementary data to create mappings between national drug terminology and RxN/E. Our method yields fine-grained mappings, enabling precise and comprehensive drug data integration for secondary use.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Semiautomatic mapping of a national drug terminology to standardised OMOP drug concepts using publicly available supplementary information

  • Florian Katsch,
  • Ágota Mészáros,
  • Tibor Héja,
  • Rada Hussein,
  • Georg Duftschmid

摘要

Background

Mapping national drug terminologies to internationally recognized standards is essential for harmonising health data across regions and supporting secondary data use. In Austria, the national drug terminology lacks fine-granular mappings to RxNorm and RxNorm Extension (RxN/E), limiting its integration into the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). This study aims to semiautomatically map Austria’s national drug terminology to RxN/E, to enable improved interoperability and data standardisation for secondary use.

Methods

We implemented a semiautomated mapping approach using public supplementary data to bridge the gap between national drug concepts and RxN/E concepts. Probabilistic matching and hierarchical refinement techniques were applied to derive finer-grained and more meaningful mappings than previously available ingredient level mappings via the Anatomical Therapeutic Chemical (ATC) classification. We linked our mappings to other available European drug mappings for a validation of our results.

Results

Our process successfully mapped 18,390 (95.42%) of Austria’s 19,273 drug concepts to RxN/E, surpassing previous mappings that focused solely on ingredient-level relationships. Specifically, we mapped 73.65% of the concepts to more specific RxN/E targets, such as branded drug boxes and quantified clinical drugs. We identified multiple vocabulary inconsistencies, including duplications and erroneous relationships within RxN/E, which were documented for improvement. The results are disseminated as Usagi-formatted CSV files and HL7 FHIR ConceptMaps to encourage transparency, ease of use, and community-driven refinement.

Conclusions

The presented mapping approach highlights the feasibility and utility of leveraging publicly available supplementary data to create mappings between national drug terminology and RxN/E. Our method yields fine-grained mappings, enabling precise and comprehensive drug data integration for secondary use.